ClinicalTrials.gg
RecruitingNCT07312526Updated Nov 13, 2026

Shanghai Clinical Cohort - Esophageal Cancer

An observational study in Esophageal Cancer and Esophagectomy, sponsored by Shanghai Chest Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Shanghai Chest Hospital · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 13, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Esophageal Neoplasms by Shanghai Chest Hospital — 7 open to participants now, 8 under way, 1 of them phase 3. Esophageal Neoplasms · Shanghai Chest Hospital.

Started
2025
with 1 other
Observational
4 of 13
2 open now
Registered
13th of 13
by date

Among the 13 studies in Esophageal Neoplasms by Shanghai Chest Hospital, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 13th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

7 of the 13 studies in Esophageal Neoplasms by Shanghai Chest Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Esophageal Neoplasms by Shanghai Chest Hospital, or all of them as a file.
02

Study summary

A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.

Read the detailed description

A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.

03

Conditions studied

  • Esophageal Cancer
  • Esophagectomy

Keywords

  • esophageal cancer
  • esophagecomy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients received esophagectomy for esophageal cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Received esophagectomy in these centers for esophageal cancer.

Exclusion criteria

Exclusion Criteria:

  • No esophagectomy.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,500 participants (estimated)
Patient registry
No

Interventions

  • Procedureesophagectomy

    esophagectomy

06

What researchers measure

Primary outcomes

  1. Overal survival

    Time frame: From the date of enrollment until the date of death or loss of follow-up, assessed up to 10 years. Follow-up is scheduled every 3 months in the first 2 years. Every 6 months from the 2nd to the 5th year. Then once a year. Until death or loss of follow.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Mar 2026, 8 months.

Of 152 non-industry observational studies under Esophageal Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 252. This study's 8 months is below that.

Counting every sponsor, half of 174 studies reached it within 64 months; a quarter within 33 and three quarters within 252.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → Dec 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 31, 2025
StartActual
Jul 1, 2025
Primary completionActual
Mar 31, 2026
CompletionEst.
Dec 31, 2026was Mar 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Nov 13, 2026
Sites
Shanghai Chest Hospital is now Recruiting
Nov 13, 2026
Study completion
Mar 31, 2026→Dec 31, 2026
Nov 13, 2026
Enrollment
2116 (actual)→3500 (estimated)
Nov 13, 2026
Contact
Study contact now listed: added z•••@shsmu.edu.cn · •••9260. See the current contact
Nov 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Shanghai Chest Hospital · Shanghai, ChinaContact added y•••@sjtu.edu.cn · •••7165
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Completed→Recruiting
    Shanghai Chest Hospital is now Recruiting
    Study completion Mar 31, 2026→Dec 31, 2026
    Enrollment 2116 (actual)→3500 (estimated)
    Contact Study contact now listed: added z•••@shsmu.edu.cn · •••9260. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Shanghai Chest Hospital · Shanghai, ChinaContact added y•••@sjtu.edu.cn · •••7165
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07312526
Collaborators
Shanghai Zhongshan Hospital, Shanghai Cancer Hospital, China, Changhai Hospital
Responsible party
Zhigang Li (Prof., Shanghai Chest Hospital) — Principal investigator
First posted
Dec 31, 2025
Start date
Jul 1, 2025
Primary completion
Mar 31, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Nov 13, 2026

Study contacts

Zhigang Li, Prof.
Contact
zhigang.li@shsmu.edu.cn
18930619260

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion